Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Director · Chief Executive Officer · 10% owner | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TREACE MEDICAL CONCEPTS, INC.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,404,383 |
Last balance in matching sequence
After 2026-08-24 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-08-20 · Purchase · Acquired 39,944 · Balance 7,388,383 F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3198 to $4.5048 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2: Includes 542,784 restricted stock units. Row 2 · 2026-08-21 · Purchase · Acquired 5,000 · Balance 7,393,383 F2: Includes 542,784 restricted stock units. Row 3 · 2026-08-24 · Purchase · Acquired 11,000 · Balance 7,404,383 F3: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3097 to $4.3489 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2: Includes 542,784 restricted stock units. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse | 1,605,000 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,605,000 F4: The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy spouse as trustee of a trust | 1,471,250 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,471,250 F4: The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectAs trustee of a trust | 1,839,063 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,839,063 F5: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee. |
| Common StockSEC Table I · non-derivative | IndirectAs co-trustee of a trust | 408,816 |
Reported balance
Holding disclosure · report date 2026-08-20 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 408,816 F5: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3198 to $4.5048 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F2: Includes 542,784 restricted stock units.
F3: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3097 to $4.3489 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F4: The Reporting Person disclaims beneficial ownership of shares held by his wife directly or in trusts for which his wife serves as trustee or co-trustee.
F5: The Reporting Person disclaims beneficial ownership of shares held in trust for which he serves as trustee or co-trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2026 Filed Aug 24, 2026 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 11,000 | $4.34 | $47,731.20 |
DisclosureSEC source: 0001193125-26-363737 · ownership.xml · nonDerivative · entry 3 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,404,383 F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3097 to $4.3489 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| August 21, 2026 Filed Aug 24, 2026 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 5,000 | $4.35 | $21,747.50 |
DisclosureSEC source: 0001193125-26-363737 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,393,383 F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 39,944 | $4.44 | $177,175.61 |
DisclosureSEC source: 0001193125-26-363737 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,388,383 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3198 to $4.5048 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 11, 2026 20:52 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 22,887 | $4.04 | $92,541.30 |
DisclosureSEC source: 0001193125-26-267800 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,376,150 F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9600 to $4.1700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 12, 2026 13:26 UTC Amendment | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 9,891 | $4.04 | $39,982.39 |
DisclosureSEC source: 0001193125-26-268606 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,348,439 F4 · shares: The original Form 4, filed on June 11, 2026, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a purchase that occurred on June 11, 2026 as a total of 22,887 shares purchased when in fact 9,891 shares of the Issuer's common stock were purchased. F5 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9600 to $4.1700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:52 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 29,430 | $4.02 | $118,426.32 |
DisclosureSEC source: 0001193125-26-267800 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,353,263 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9300 to $4.1000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 13:26 UTC Amendment | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 14,715 | $4.02 | $59,213.16 |
DisclosureSEC source: 0001193125-26-268606 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,338,548 F1 · shares: The original Form 4, filed on June 11, 2026, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported a purchase that occurred on June 10, 2026 as a total of 29,430 shares purchased when in fact 14,715 shares of the Issuer's common stock were purchased. F2 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.9300 to $4.1000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| June 01, 2026 Filed Jun 1, 2026 20:38 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 50,000 | $3.56 | $177,915.00 |
DisclosureSEC source: 0001193125-26-251587 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,323,833 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $3.5100 to $3.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| May 28, 2026 Filed May 28, 2026 20:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 61,202 | $3.02 | $184,823.92 |
DisclosureSEC source: 0001193125-26-245341 · ownership.xml · nonDerivative · entry 3 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,273,833 F5 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.8233 to $3.1150 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 49,810 | $2.87 | $143,188.81 |
DisclosureSEC source: 0001193125-26-245341 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,212,631 F4 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.7976 to $2.9400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 4,508 | $2.79 | $12,575.97 |
DisclosureSEC source: 0001193125-26-245341 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,162,821 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.7600 to $2.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| May 14, 2026 Filed May 14, 2026 21:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 61,750 | $2.62 | $161,494.78 |
DisclosureSEC source: 0001193125-26-224391 · ownership.xml · nonDerivative · entry 3 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,158,313 F4 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.4950 to $2.8000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units Read SEC document |
| May 13, 2026 Filed May 14, 2026 21:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 49,013 | $2.46 | $120,532.77 |
DisclosureSEC source: 0001193125-26-224391 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,096,563 F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $2.3850 to $2.5000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units Read SEC document |
| May 12, 2026 Filed May 14, 2026 21:33 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 43,000 | $2.17 | $93,477.70 |
DisclosureSEC source: 0001193125-26-224391 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,047,550 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $1.9100 to $2.2800 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 542,784 restricted stock units Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 5,021 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102762 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,004,550 F2 · balance_after: Includes 542,784 restricted stock units. Read SEC document |
| March 08, 2026 Filed Mar 12, 2026 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 2,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-102762 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,009,571 F1 · balance_after: Includes 563,403 restricted stock units. Read SEC document |
| January 22, 2026 Filed Jan 24, 2026 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-021449 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,011,633 F2 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date. F3 · balance_after: Includes 571,871 restricted stock units. Read SEC document |
| January 22, 2026 Filed Jan 24, 2026 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 14,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-021449 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,761,633 F1 · balance_after: Includes 321,871 restricted stock units. Read SEC document |
| January 10, 2026 Filed Jan 14, 2026 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 13,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-012080 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,775,887 F1 · balance_after: Includes 363,867 restricted stock units. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 5,021 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-037574 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,789,106 F2 · balance_after: Includes 408,448 restricted stock units Read SEC document |
| March 08, 2025 Filed Mar 12, 2025 01:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 2,063 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-037574 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,794,127 F1 · balance_after: Includes 429,067 restricted stock units Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 23:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 60,000 | $8.73 | $524,064.00 |
DisclosureSEC source: 0000950170-25-032626 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,796,190 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $8.3150 to $8.9400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 437,536 restricted stock units Read SEC document |
| January 22, 2025 Filed Jan 25, 2025 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-008971 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,736,190 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2026 and the last installment vesting on January 22, 2029; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 437,536 restricted stock units Read SEC document |
| January 10, 2025 Filed Jan 15, 2025 02:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 11,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-005577 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,511,190 F1 · balance_after: Includes 151,882 restricted stock units Read SEC document |
| September 16, 2024 Filed Sep 17, 2024 21:17 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 50,000 | $5.31 | $265,630.00 |
DisclosureSEC source: 0000950170-24-107401 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,523,095 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.0550 to $5.5000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 196,464 restricted stock units Read SEC document |
| August 14, 2024 Filed Aug 15, 2024 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 85,000 | $6.00 | $510,314.50 |
DisclosureSEC source: 0000950170-24-097694 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,473,095 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.9500 to $6.0700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 196,464 restricted stock units Read SEC document |
| June 11, 2024 Filed Jun 11, 2024 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 45,000 | $5.88 | $264,600.00 |
DisclosureSEC source: 0000950170-24-072078 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,388,095 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.6800 to $5.9100 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 196,464 restricted stock units Read SEC document |
| May 17, 2024 Filed May 20, 2024 20:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 100,000 | $5.56 | $556,170.00 |
DisclosureSEC source: 0000950170-24-062435 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,343,095 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $5.3943 to $5.7480 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 196,464 restricted stock units Read SEC document |
| May 14, 2024 Filed May 14, 2024 22:19 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 150,000 | $5.12 | $767,805.00 |
DisclosureSEC source: 0000950170-24-059854 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,243,095 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.9800 to $5.3500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 196,646 restricted stock units Read SEC document |
| May 13, 2024 Filed May 13, 2024 22:07 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 150,000 | $4.56 | $683,490.00 |
DisclosureSEC source: 0000950170-24-058878 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,093,095 F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.3900 to $4.6400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 196,646 restricted stock units Read SEC document |
| May 10, 2024 Filed May 13, 2024 22:07 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 150,000 | $4.58 | $686,880.00 |
DisclosureSEC source: 0000950170-24-058878 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,943,095 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $4.4700 to $4.7500 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 196,646 restricted stock units Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 01:55 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 5,021 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-030472 · ownership.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,793,095 F2 · balance_after: Includes 196,646 restricted stock units Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:55 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 2,064 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-030472 · ownership.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,798,116 F1 · balance_after: Includes 201,667 restricted stock units Read SEC document |
| January 10, 2024 Filed Jan 13, 2024 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 178,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001590 · doc4.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,800,180 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 10, 2025 with the last installment vesting on January 10, 2028; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 203,731 restricted stock units. Read SEC document |
| March 10, 2023 Filed Mar 11, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 186,900 | $0.00 Strike: $24.07 | $0.00 |
DisclosureSEC source: 0001209191-23-018046 · doc4.xml · derivative · entry 7 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,900 Underlying: Stock Option (Right to Buy) · 186,900 shares Expires 2033-03-10 F7 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on March 10, 2024 with the last installment on March 10, 2027; subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| March 10, 2023 Filed Mar 11, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 82,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018046 · doc4.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,621,855 F3 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 10, 2024 with the last installment on March 10, 2027; subject to Reporting Person's providing continued service to Issuer through each vesting date. F4 · balance_after: Includes 107,881 RSUs. Read SEC document |
| March 09, 2023 Filed Mar 11, 2023 02:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 2,075 | $24.41 | $50,650.75 |
DisclosureSEC source: 0001209191-23-018046 · doc4.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,539,380 F1 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes 25,406 restricted stock units. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 23:27 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 15,000 | $21.83 | $327,405.00 |
DisclosureSEC source: 0001209191-22-058266 · doc4.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,541,455 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $21.5500 to $21.9700 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 33,875 restricted stock units. Read SEC document |
| November 17, 2022 Filed Nov 17, 2022 22:55 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 10,000 | $21.67 | $216,714.00 |
DisclosureSEC source: 0001209191-22-057654 · doc4.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,526,455 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $21.5450 to $21.7300 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 33,875 restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 21:21 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 10,000 | $19.80 | $198,031.00 |
DisclosureSEC source: 0001209191-22-048290 · doc4.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,516,455 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $19.6650 to $19.8900 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 33,875 restricted stock units. Read SEC document |
| August 26, 2022 Filed Aug 29, 2022 13:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 21,491 | $20.95 | $450,341.76 |
DisclosureSEC source: 0001209191-22-047786 · doc4.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,506,455 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $20.9000 to $20.9600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 33,875 restricted stock units. Read SEC document |
| August 24, 2022 Filed Aug 24, 2022 23:23 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 509 | $18.92 | $9,631.91 |
DisclosureSEC source: 0001209191-22-047407 · doc4.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,484,964 F3 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $18.88 to $18.99 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 33,875 restricted stock units. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 23:23 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | PurchaseCommon Stock | 28,000 | $18.72 | $524,123.60 |
DisclosureSEC source: 0001209191-22-047407 · doc4.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Offer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,484,455 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were bought in multiple transactions at prices ranging from $18.28 to $19.01 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 33,875 restricted stock units. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:24 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 20,884 | $0.00 Strike: $21.07 | $0.00 |
DisclosureSEC source: 0001567619-22-006730 · doc1.xml · derivative · entry 7 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,884 Underlying: Common Stock · 20,884 shares Expires 2027-03-08 F3 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:24 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantStock Option (Right to Buy) · Derivative | 240,566 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001567619-22-006730 · doc1.xml · derivative · entry 6 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,566 Underlying: Common Stock · 240,566 shares Expires 2032-03-08 F3 · derivative.exercise_date: The stock option will vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026; subject to Reporting Person's providing continued service to Issuer through each vesting date. Read SEC document |
| March 08, 2022 Filed Mar 11, 2022 01:24 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 33,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-006730 · doc1.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,456,455 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, commencing on March 8, 2023 with the last installment on March 8, 2026? subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 33,875 RSUs. Read SEC document |
| December 29, 2021 Filed Dec 30, 2021 23:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 3,075 | $17.01 | $52,314.98 |
DisclosureSEC source: 0001567619-21-022717 · doc1.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,422,580 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.00 to $ $17.06 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 23:01 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 19,760 | $16.99 | $335,803.42 |
DisclosureSEC source: 0001567619-21-022717 · doc1.xml · nonDerivative · entry 1 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,425,655 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.585 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 01:10 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 17,165 | $17.44 | $299,373.05 |
DisclosureSEC source: 0001567619-21-022542 · doc1.xml · nonDerivative · entry 3 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,445,415 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.61 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 01:10 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | SaleCommon Stock | 22,795 | $16.96 | $386,541.65 |
DisclosureSEC source: 0001567619-21-022542 · doc1.xml · nonDerivative · entry 2 Treace John T. · CIK 0001856380 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,462,580 F1 · kind: Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.50 to $ $17.29 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.